Kelsey Gauthier
About Kelsey Gauthier
Kelsey Gauthier serves as the Director of Biology at Arcus Biosciences, where she focuses on pipeline target biology and pharmacology research. With a Ph.D. in Microbiology and Immunology, she has extensive experience in translating scientific discoveries into therapeutic applications.
Current Role at Arcus Biosciences
Kelsey Gauthier serves as the Director of Biology at Arcus Biosciences, a position held since 2021. In this role, she focuses on pipeline target biology and pharmacology research. Her work emphasizes the development of treatments with therapeutic potential, contributing to the company's mission of advancing cancer therapies. Gauthier's leadership in the biology department plays a crucial role in bridging scientific discovery with clinical application.
Previous Experience at Arcus Biosciences
Prior to her current role, Kelsey Gauthier worked as a Research Fellow in Biology at Arcus Biosciences from 2019 to 2021. During her two years in this position, she contributed to research initiatives aimed at understanding biological targets relevant to cancer treatment. Her experience at Arcus laid the groundwork for her subsequent promotion to Director.
Academic Background and Education
Kelsey Gauthier obtained her Bachelor of Science degree in Microbiology, Biochemistry, and Molecular Biology from Penn State University, completing her studies from 2000 to 2004. She then pursued her Ph.D. in Microbiology and Immunology at the University of Michigan Medical School, where she studied from 2004 to 2010. This rigorous academic background provided her with a strong foundation in biological sciences.
Research Contributions and Expertise
Kelsey Gauthier has a strong focus on research that connects scientific discovery to clinical applications, particularly in biology. She has expertise in pipeline target biology and pharmacology, aiming to translate research findings into therapeutic solutions. Her contributions include research on Fc-silent anti-TIGIT antibodies, HIF-2α inhibitors, and dual A2aR/A2bR antagonism with etrumadenant.
Professional Engagement and Presentations
Kelsey Gauthier has actively engaged with the scientific community through presentations at notable conferences, including the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC). These presentations highlight her research findings and contribute to the broader discourse in cancer biology and immunotherapy.